Allergan Says Judge Erred in Allowing Investor Suit

Allergan Inc. investors should be barred from seeking to hold directors responsible for a $600 million penalty the maker of the wrinkle smoother Botox had to pay over illegal marketing of the drug, the company’s lawyers told Delaware’s high court.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.